Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) posted its quarterly earnings results on Thursday. Here are the key takeaways from Lineage Cell Therapeutics’ conference call:Get Lineage Cell Therapeutics alerts:Cash runway extended into Q3 2028 : Lineage reported $50.8 million in cash, cash equivalents, and marketable securities, aided by a $4.6 million ATM raise. Lineage Cell Therapeutics has a one year low of $0.95 and a one year high of $2.09. Get Our Latest Research Report on LCTXLineage Cell Therapeutics Company Profile(Get Free Report)Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. Featured StoriesReceive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.